Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Reply to Barner and Bruno-Murtha.

Kullar R, Nagel J, Bleasdale SC, Sutton SH, Naumovski S, Smith C, Leggett J, Wollins D, Busky C, Goldstein EJC.

Clin Infect Dis. 2019 Sep 23. pii: ciz935. doi: 10.1093/cid/ciz935. [Epub ahead of print] No abstract available.

PMID:
31544204
2.

Whole Genome Sequencing to Identify Drivers of Carbapenem-Resistant Klebsiella pneumoniae Transmission Within and Between Regional Long-Term Acute Care Hospitals.

Han JH, Lapp Z, Bushman F, Lautenbach E, Goldstein EJC, Mattei L, Hofstaedter CE, Kim D, Nachamkin I, Garrigan C, Jain T, Bilker W, Wolford HM, Slayton RB, Wise J, Tolomeo P, Snitkin ES.

Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.01622-19. doi: 10.1128/AAC.01622-19. [Epub ahead of print]

PMID:
31451495
3.

The Influence of Microaffirmations on Undergraduate Persistence in Science Career Pathways.

Estrada M, Young GR, Nagy J, Goldstein EJ, Ben-Zeev A, Márquez-Magaña L, Eroy-Reveles A.

CBE Life Sci Educ. 2019 Sep;18(3):ar40. doi: 10.1187/cbe.19-01-0012.

PMID:
31441717
4.

Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk.

Goldstein EJ, Bell DJ, Gunson RN.

BMJ Case Rep. 2019 May 13;12(5). pii: e229558. doi: 10.1136/bcr-2019-229558.

PMID:
31088820
5.

U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.

Thorpe CM, McDermott LA, Tran MK, Chang J, Jenkins SG, Goldstein EJC, Patel R, Forbes BA, Johnson S, Gerding DN, Snydman DR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00391-19. doi: 10.1128/AAC.00391-19. Print 2019 Jul.

PMID:
31085514
6.

Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection.

Tran MN, Kullar R, Goldstein EJC.

Expert Opin Investig Drugs. 2019 Apr;28(4):323-335. doi: 10.1080/13543784.2019.1581763. Epub 2019 Feb 26. Review.

PMID:
30753786
7.

Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

Sniffen JC, McFarland LV, Evans CT, Goldstein EJC.

PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018.

8.

In-house validation of the cobas Liat influenza A/B and RSV assay for use with gargles, sputa and endotracheal secretions.

Goldstein EJ, Gunson RN.

J Hosp Infect. 2019 Mar;101(3):289-291. doi: 10.1016/j.jhin.2018.10.025. Epub 2018 Nov 5. No abstract available.

PMID:
30408505
9.

Going for the Gold: A Description of the Centers of Excellence Designation by the Infectious Diseases Society of America.

Kullar R, Nagel J, Bleasdale SC, Sutton SH, Naumovski S, Rodriguez A, Smith C, Leggett J, Goldstein EJC.

Clin Infect Dis. 2019 May 2;68(10):1777-1782. doi: 10.1093/cid/ciy797.

PMID:
30239608
10.

In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.

Tyrrell KL, Citron DM, Merriam CV, Leoncio E, Goldstein EJC.

Anaerobe. 2018 Dec;54:39-41. doi: 10.1016/j.anaerobe.2018.04.010. Epub 2018 Apr 13.

PMID:
30096588
11.

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species.

Goldstein EJC, Citron DM, Tyrrell KL.

Anaerobe. 2018 Aug;52:122-124. doi: 10.1016/j.anaerobe.2018.06.016. Epub 2018 Jul 4.

PMID:
30018028
12.
13.

Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.

Cheknis A, Johnson S, Chesnel L, Petrella L, Sambol S, Dale SE, Nary J, Sears P, Citron DM, Goldstein EJC, Gerding DN.

Anaerobe. 2018 Oct;53:38-42. doi: 10.1016/j.anaerobe.2018.05.009. Epub 2018 May 26.

PMID:
29886050
14.

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

McFarland LV, Evans CT, Goldstein EJC.

Front Med (Lausanne). 2018 May 7;5:124. doi: 10.3389/fmed.2018.00124. eCollection 2018.

15.

Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates.

Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriam CV.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02551-17. doi: 10.1128/AAC.02551-17. Print 2018 Apr.

16.

Integrating patient and whole-genome sequencing data to provide insights into the epidemiology of seasonal influenza A(H3N2) viruses.

Goldstein EJ, Harvey WT, Wilkie GS, Shepherd SJ, MacLean AR, Murcia PR, Gunson RN.

Microb Genom. 2018 Jan;4(1). doi: 10.1099/mgen.0.000137. Epub 2017 Dec 21.

17.

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.

Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriam CV.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01992-17. doi: 10.1128/AAC.01992-17. Print 2018 Feb.

18.

Corrigendum: Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibacterium rodentium.

Cox LM, Sohn J, Tyrrell KL, Citron DM, Lawson PA, Patel NB, Iizumi T, Perez-Perez GI, Goldstein EJC, Blaser MJ.

Int J Syst Evol Microbiol. 2017 Oct;67(10):4289. doi: 10.1099/ijsem.0.002339. No abstract available.

19.

In Vitro Activities of Pexiganan and 10 Comparator Antimicrobials against 502 Anaerobic Isolates Recovered from Skin and Skin Structure Infections.

Goldstein EJC, Citron DM, Tyrrell KL, Leoncio ES.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01401-17. doi: 10.1128/AAC.01401-17. Print 2017 Dec.

20.

'Speaking Truth' Protects Underrepresented Minorities' Intellectual Performance and Safety in STEM.

Ben-Zeev A, Paluy Y, Milless KL, Goldstein EJ, Wallace L, Márquez-Magaña L, Bibbins-Domingo K, Estrada M.

Educ Sci (Basel). 2017 Jun;7(2). pii: 65. doi: 10.3390/educsci7020065. Epub 2017 Jun 19.

21.

In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds.

Goldstein EJC, Citron DM, Tyrrell KL, Leoncio ES.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00246-17. doi: 10.1128/AAC.00246-17. Print 2017 Jun.

22.

Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Wenzler E, Goff DA, Humphries R, Goldstein EJC.

Infect Dis Ther. 2017 Jun;6(2):149-172. doi: 10.1007/s40121-017-0149-y. Epub 2017 Mar 4. Review.

23.

Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting.

Abrahamian FM, Talan DA, Krishnadasan A, Citron DM, Paulick AL, Anderson LJ, Goldstein EJC, Moran GJ; EMERGEncy ID NET Study Group.

Ann Emerg Med. 2017 Jul;70(1):19-27.e4. doi: 10.1016/j.annemergmed.2016.12.013. Epub 2017 Feb 24.

PMID:
28242058
24.

Effects of control interventions on Clostridium difficile infection in England: an observational study.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, Harding RM, Wilson DJ, Griffiths D, Vaughan A, Finney JM, Wyllie DH, Oakley SJ, Fawley WN, Freeman J, Morris K, Martin J, Howard P, Gorbach S, Goldstein EJC, Citron DM, Hopkins S, Hope R, Johnson AP, Wilcox MH, Peto TEA, Walker AS, Crook DW; Modernising Medical Microbiology Informatics Group.

Lancet Infect Dis. 2017 Apr;17(4):411-421. doi: 10.1016/S1473-3099(16)30514-X. Epub 2017 Jan 25.

25.

Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibaculum rodentium.

Cox LM, Sohn J, Tyrrell KL, Citron DM, Lawson PA, Patel NB, Iizumi T, Perez-Perez GI, Goldstein EJC, Blaser MJ.

Int J Syst Evol Microbiol. 2017 May;67(5):1247-1254. doi: 10.1099/ijsem.0.001793. Epub 2017 May 30. Erratum in: Int J Syst Evol Microbiol. 2017 Oct;67(10 ):4289.

26.

Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals.

Han JH, Goldstein EJ, Wise J, Bilker WB, Tolomeo P, Lautenbach E.

Clin Infect Dis. 2017 Apr 1;64(7):839-844. doi: 10.1093/cid/ciw856.

27.

Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.

Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ.

J Antimicrob Chemother. 2017 Mar 1;72(3):900-905. doi: 10.1093/jac/dkw486.

PMID:
27999024
28.

Probiotics and prevention of Clostridium difficile infection.

Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV.

Anaerobe. 2017 Jun;45:114-119. doi: 10.1016/j.anaerobe.2016.12.007. Epub 2016 Dec 14. Review.

PMID:
27988389
29.

Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

Snydman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins SG, Newton D, Patel R, Hecht DW.

Anaerobe. 2017 Feb;43:21-26. doi: 10.1016/j.anaerobe.2016.11.003. Epub 2016 Nov 17.

PMID:
27867083
30.

A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.

Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, Cairns KA, Escandón-Vargas K, Villegas MV, Brink A, van den Bergh D, Mendelson M.

Lancet Infect Dis. 2017 Feb;17(2):e56-e63. doi: 10.1016/S1473-3099(16)30386-3. Epub 2016 Nov 18. Review.

PMID:
27866945
31.

Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.

Chopra T, Goldstein EJ, Gorbach SL.

Pharmacotherapy. 2016 Dec;36(12):1281-1289. doi: 10.1002/phar.1863. Review.

PMID:
27862113
32.

The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.

Goldstein EJ, Citron DM, Tyrrell KL, Leoncio ES, Merriam CV.

Anaerobe. 2017 Feb;43:1-3. doi: 10.1016/j.anaerobe.2016.09.008. Epub 2016 Oct 3.

PMID:
27713022
33.

Ridinilazole: a novel therapy for Clostridium difficile infection.

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH.

Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Review.

34.

Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines.

Goldstein EJ, Goff DA, Reeve W, Naumovski S, Epson E, Zenilman J, Kaye KS, File TM Jr.

Clin Infect Dis. 2016 Aug 15;63(4):532-8. doi: 10.1093/cid/ciw247. Epub 2016 Apr 20.

PMID:
27098167
35.

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ.

J Antimicrob Chemother. 2016 Jul;71(7):2014-21. doi: 10.1093/jac/dkw053. Epub 2016 Mar 18.

PMID:
26994090
36.

Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability.

Tyrrell KL, Citron DM, Leoncio ES, Goldstein EJ.

J Clin Microbiol. 2016 May;54(5):1364-7. doi: 10.1128/JCM.03246-15. Epub 2016 Feb 17.

37.

Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.

Citron DM, Tyrrell KL, Dale SE, Chesnel L, Goldstein EJ.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2069-74. doi: 10.1128/AAC.02531-15. Print 2016 Apr.

38.

Diseases Transmitted by Cats.

Goldstein EJC, Abrahamian FM.

Microbiol Spectr. 2015 Oct;3(5). doi: 10.1128/microbiolspec.IOL5-0013-2015. Review.

PMID:
26542039
39.

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG, Goldstein EJ, Patel R, Forbes BA, Mirrett S, Johnson S, Gerding DN.

Antimicrob Agents Chemother. 2015 Oct;59(10):6437-43. doi: 10.1128/AAC.00845-15. Epub 2015 Aug 3.

40.

Animals in healthcare facilities: recommendations to minimize potential risks.

Murthy R, Bearman G, Brown S, Bryant K, Chinn R, Hewlett A, George BG, Goldstein EJ, Holzmann-Pazgal G, Rupp ME, Wiemken T, Weese JS, Weber DJ.

Infect Control Hosp Epidemiol. 2015 May;36(5):495-516. doi: 10.1017/ice.2015.15. Review. No abstract available.

PMID:
25998315
41.

Reply to Solnick.

Goldstein EJ, Saravolatz LD.

Clin Infect Dis. 2015 Aug 1;61(3):484-5. doi: 10.1093/cid/civ356. Epub 2015 May 8. No abstract available.

PMID:
25956894
42.

Lactobacillus species: taxonomic complexity and controversial susceptibilities.

Goldstein EJ, Tyrrell KL, Citron DM.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S98-107. doi: 10.1093/cid/civ072. Review.

PMID:
25922408
43.

Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship.

Chopra T, Goldstein EJ.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S72-6. doi: 10.1093/cid/civ053. Review.

PMID:
25922404
44.

Pathway to Prevention of Nosocomial Clostridium difficile Infection.

Goldstein EJ, Johnson S, Maziade PJ, McFarland LV, Trick W, Dresser L, Millette M, Mazloum H, Low DE.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S148-58. doi: 10.1093/cid/civ142.

PMID:
25922401
46.

The times they are a-changin': new antibacterials for skin and skin structure infections.

Tran MC, Naumovski S, Goldstein EJ.

Am J Clin Dermatol. 2015 Jun;16(3):137-46. doi: 10.1007/s40257-015-0125-9. Review.

PMID:
25906205
47.

Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.

Lipsky BA, Cannon CM, Ramani A, Jandourek A, Calmaggi A, Friedland HD, Goldstein EJ.

Diabetes Metab Res Rev. 2015 May;31(4):395-401. doi: 10.1002/dmrr.2624. Epub 2015 Jan 23.

PMID:
25417910
48.

Clostridium difficile: improving the prevention paradigm in healthcare settings.

Vassallo A, Tran MC, Goldstein EJ.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1087-102. doi: 10.1586/14787210.2014.942284. Review.

PMID:
25109301
49.

Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Achermann Y, Goldstein EJ, Coenye T, Shirtliff ME.

Clin Microbiol Rev. 2014 Jul;27(3):419-40. doi: 10.1128/CMR.00092-13. Review.

50.

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1448. Dosage error in article text.

PMID:
24973422

Supplemental Content

Loading ...
Support Center